Snoop Dogg’s Venture Firm Boosts UK Cannabis Clinic with £4.5M Investment

LONDON – Casa Verde Capital, co-founded by rapper Snoop Dogg, has pumped £4.5 million [$6 million] into Mamedica, the United Kingdom’s dominant online provider of medical Cannabis prescriptions, in what stands as the biggest funding round yet for a telehealth player in the sector.

The Series A investment, announced this week and led by Casa Verde, comes at a time when Britain’s tightly regulated medical Cannabis industry shows signs of picking up steam. Mamedica, which specializes in virtual consultations and home deliveries for patients with conditions like chronic pain and epilepsy, plans to use the cash to broaden its offerings, ramp up research efforts, and handle a surge in demand.

Casa Verde Capital, a longtime Cannabis advocate with its own line of branded products, brings more than just checkbook muscle. The firm has backed over 100 startups worldwide since 2015, focusing on everything from cultivation tech to patient access platforms. Karan Wadhera and Tony Ghanem, key figures at Casa Verde, will guide Mamedica’s push into international waters, tapping the fund’s connections in North America and beyond.

This infusion arrives as the UK medical Cannabis market, legalized for prescriptions since 2018, inches toward broader acceptance. Data from market trackers paint a picture of measured expansion: The sector generated about $12.5 million in revenue last year, with projections pointing to $62.8 million by 2030, according to Grand View Research. Patient registrations have climbed steadily, though growth hovers in the low single digits month to month, per recent industry reports. Private clinics like Mamedica fill a gap left by the National Health Service, which rarely covers Cannabis treatments due to sparse evidence on efficacy.

From an investor’s angle, the bet underscores a calculated optimism. Telehealth models cut costs and reach underserved areas, especially in a country where in-person specialist visits can drag on for months. Mamedica’s edge lies in its streamlined process: Patients upload records online, chat with doctors via video and get meds shipped discreetly. Yet the funding also highlights persistent friction points. Regulatory scrutiny remains fierce [the Medicines and Healthcare products Regulatory Agency demands rigorous proof of benefits] and reimbursement battles with insurers could slow scaling.

Critics might question the timing, given that Cannabis prescriptions still account for less than 1% of the UK’s overall pain management market. But backers see untapped potential in demographics like veterans and multiple sclerosis sufferers, where anecdotal successes abound. This deal could nudge competitors to digitize faster, pressuring brick-and-mortar outfits to adapt or consolidate.

This move by Casa Verde signals a maturing cross-border flow of capital into Europe’s Cannabis scene. Here, at Highly Capitalized Network, as the industry watcher with a front-row seat to mergers and policy shifts, we view it as a pragmatic play; not a moonshot, but a solid step that bolsters patient options without overpromising on overnight transformation. In a field where evidence builds slowly and rules change deliberately, such targeted growth keeps the sector credible and competitive. Expect ripple effects in research output and prescription volumes over the next 18 months; they could define whether UK Cannabis care truly breaks into the mainstream.